Liu Jinyan, Zhang Yi
Biotherapy Center and Cancer Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou, Henan, China.
Biomark Res. 2022 May 31;10(1):37. doi: 10.1186/s40364-022-00381-5.
Cancer is a complicated disease attributed to multifactorial changes, which causes difficulties with treatment strategies. Various factors have been regarded as the main contributors, and infectious etiological factors have recently attracted interest. Several microbiomes contribute to carcinogenesis, cancer progression, and modulating cancer treatment by inducing cancerous epithelial cells and chronic inflammation. Most of our knowledge on the role of microbiota in tumor oncogenesis and clinical efficiency is associated with the intestinal microbiome. However, compelling evidence has also confirmed the contribution of the intratumor microbiome in cancer. Indeed, the findings of clinical tumor samples, animal models, and studies in vitro have revealed that many intratumor microbiomes promote tumorigenesis and immune evasion. In addition, the intratumor microbiome participates in regulating the immune response and even affects the outcomes of cancer treatment. This review summarizes the interplay between the intratumor microbiota and cancer, focusing on the contribution and mechanism of intratumor microbiota in cancer initiation, progression, and potential applications to cancer therapy.
癌症是一种由多因素变化引起的复杂疾病，这给治疗策略带来了困难。各种因素被认为是主要促成因素，而传染性病因因素最近引起了关注。几种微生物群落通过诱导癌细胞上皮细胞和慢性炎症，对致癌作用、癌症进展和调节癌症治疗产生影响。我们目前对微生物群在肿瘤发生和临床疗效方面作用的了解大多与肠道微生物群有关。然而，确凿的证据也证实了肿瘤内微生物群在癌症中的作用。事实上，临床肿瘤样本、动物模型和体外研究的结果表明，许多肿瘤内微生物群促进肿瘤发生和免疫逃逸。此外，肿瘤内微生物群参与调节免疫反应，甚至影响癌症治疗的结果。本综述总结了肿瘤内微生物群与癌症之间的相互作用，重点关注肿瘤内微生物群在癌症发生、发展中的作用机制以及在癌症治疗中的潜在应用。
